Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 17/20 | 0.67 |
| ▸ | GABRP | O00591 | 1/20 | 0.57 |
| ▸ | GABRD | O14764 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
| ▸ | GABRE | P78334 | 1/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.57 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.57 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.57 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.56 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505896 | 1.00 | HCAR3 (0.67) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Ammonia Solution, Strong SCHEMBL28249483 | 0.98 | HCAR3 (0.65) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL5789616 | 0.98 | HCAR3 (0.65) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Acetone SCHEMBL7024428 | 0.94 | HCAR3 (0.66) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinic Acid SCHEMBL23070477 | 0.91 | HCAR3 (0.57) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinimide SCHEMBL28163974 | 0.87 | HCAR3 (0.53) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinimide SCHEMBL25397856 | 0.86 | HCAR3 (0.51) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Benzaldehyde SCHEMBL27567924 | 0.86 | HCAR3 (0.55) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8722229 | 0.84 | NNMT (0.50) | HCAR3HCAR2 | |
| SCHEMBL383413 | 0.84 | NNMT (0.70) | HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036881-A | Somatostatin receptor-targeting compounds and uses thereof | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260061085-A1 | CYCLIC PEPTIDE AND PREPARATION METHOD THEREFOR, AND COMPLEX COMPRISING SAME AND USE THEREOF | HEXIN SUZHOU PHARMACEUTICAL TECH CO LTD (CN) | 2026-03-05 | — | — | US | claimed |
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4612144-A1 | CARBONIC ANHYDRASE IX LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2025-09-10 | — | — | EP | claimed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | claimed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| EP-1846042-A2 | CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS | Board of Regents, The University of Texas System (US) | 2007-10-24 | — | — | EP | claimed |
| US-20070196275-A1 | Diagnostic Imaging Compositions, Their Methods Of Synthesis And Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | claimed |
| EP-1784422-A2 | GLP-1 AND EXENDIN RELATED INVENTION | Philipps-Universität Marburg (DE) | 2007-05-16 | — | — | EP | claimed |
| US-20060182687-A1 | Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-08-17 | — | — | US | claimed |
| WO-2006074272-A2 | CONJUGATES FOR DUAL IMAGING AND RADIOCHEMOTHERAPY: COMPOSITION, MANUFACTURING, AND APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-07-13 | — | — | WO | claimed |
| WO-2006024275-A2 | GLP-1 AND EXENDIN RELATED INVENTION | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2006-03-09 | — | — | WO | claimed |
| EP-1389090-A2 | DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE | Board of Regents, The University of Texas System (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030003048-A1 | Diagnostic imaging compositions, their methods of synthesis and use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-02 | — | — | US | claimed |
| WO-2002087498-A2 | DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-11-07 | — | — | WO | claimed |
| EP-0384769-B1 | Protein labelling | JOHNSON MATTHEY PLC (GB) | 1996-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061085-A1 | CYCLIC PEPTIDE AND PREPARATION METHOD THEREFOR, AND COMPLEX COMPRISING SAME AND USE THEREOF | ANPEP, XPNPEP1, SLC7A1 | HCAR3 1880/4885GABRP 1269/4885GABRD 1557/4885 |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | HCAR3 140/4885GABRP 534/4885GABRD 1238/4885 |
| US-20060182687-A1 | Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications | CCNY, B3GAT3, FUT5 | HCAR3 689/4885GABRP 4198/4885GABRD 4390/4885 |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CD47, TFRC, L1CAM | HCAR3 3729/4885GABRP 1703/4885GABRD 2748/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | HCAR3 3917/4885GABRP 3542/4885GABRD 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.